Blurbs

Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Anavex Life Sciences (AVXL) and Apellis Pharmaceuticals (APLS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regulus (RGLSResearch Report), Anavex Life Sciences (AVXLResearch Report) and Apellis Pharmaceuticals (APLSResearch Report) with bullish sentiments.

Regulus (RGLS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $20.00. The company’s shares closed last Monday at $2.10, close to its 52-week low of $1.58.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -36.2% and a 19.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Timber Pharmaceuticals, and Oncternal Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regulus with a $20.00 average price target.

See today’s best-performing stocks on TipRanks >>

Anavex Life Sciences (AVXL)

Berenberg Bank analyst Caroline Palomeque maintained a Buy rating on Anavex Life Sciences today and set a price target of $40.00. The company’s shares closed last Monday at $10.60.

According to TipRanks.com, Palomeque is ranked #7674 out of 7915 analysts.

Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $35.20.

Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals received a Buy rating and a $75.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Monday at $44.76.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.0% and a 38.9% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $74.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RGLS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos